National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021, China
Location status: Recruiting
NCT Number: NCT05762900
This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.
Interested in participating?
Request Info35 year and older
Female
Interventional
Phase 2
Beijing, 100021, China
Location status: Recruiting
During the study, the patients would undergo radiation of 5.2Gy for 5 fractions to the prophylactic radiation volumes and and a 6Gy per-fraction simultaneous boost to the tumor bed or other high-risk volumes. Acute toxicity of grade 2 or higher in the following 12 weeks after radiotherapy is the primary end point.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
Other names: Simultaneous Integrated Boost
Time frame: until 12 weeks from the completion of postoperative radiotherapy
The investigators will record the incidence of ≥ 2 degree radiation-associated acute toxicity, such as breast or chest wall oedema, acute dermatitis, breast pain,itch of breast skin; ≥ 3 degree radiation-associated esophagitis; ≥ 3 degree radiation-associated lymphopenia.
Time frame: Local recurrence rate would be recorded and reported until at least 5 years after diagnosis.
The incidence of recurrence of any invasive or non-invasive breast cancer in the ipsilateral breast or chest wall.
Time frame: Local regional recurrence rate would be recorded and reported until at least 5 years after diagnosis.
The incidence of recurrence in the ipsilateral breast/chest wall or the lymphatic nodal regions.
Time frame: Until at least 5 years after diagnosis.
The time interval from diagnosis to any event of recurrence or death.
Time frame: Until at least 5 years after diagnosis.
The time interval from diagnosis to death from any reason.
Time frame: From 12 weeks to 5 years post radiotherapy.
The investigators will record the incidence of any long-term toxicities, such as skin or subcutaneous fibrosis, pain, breast distortion, brachial plexopathy, lymphodema, cardiac event, rib fracture, pulmonary fibrosis, and so on.
Time frame: European Organization Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire EORTC QLQ-C30 to record patients' quality of life before and at 12, 24 and 60 months after radiotherapy.
European Organization for Research and Treatment of Cancer General Quality of Life Questionnaire (brev: EORTC C-30) is used. The higher the score, the worse the situation, with the range of 28 to 112.
Time frame: The patients' quality of life will be evaluated before and at 12, 24 and 60 months after radiotherapy.
European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (brev: EORTC BR-23) is used. The higher the score, the worse the situation, with the range of 23 to 92.
Time frame: The cosmetic outcome will be evaluated before and at 12, 24 and 60 months after radiotherapy.
Breast Cancer Treatment Outcome Scale 22 (brev: BCTOS 22) is used, for patients who receive breast conservative surgery. The higher the score, the worse the cosmesis, with the range of 22 to 88.
Contact information is provided by the study sponsor or research team.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Other
Ultra-hypofractioNated Radiotherapy ± sImultaneous Integrated Boost for Low-risk(risQue) Breast Cancer Patients After Breast Conservative sUrgery or mastEctomy (UNIQUE)
Acronym: UNIQUE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04889924
Axillary Lymph Nodes Dissection, Breast Cancer
Sydney, New South Wales, Australia
View Trial DetailsNCT06648148
Breast Cancer, Breast Diseases
Ljubljana, Slovenia
View Trial DetailsNCT06615466
Breast Cancer, Breast Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06321653
Arm Lymphedema, Breast Cancer
Milan, Italy
View Trial Details